1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Authors

Showing 3 results for author "John Mascarenhas".

$Thumbnail for Correlation Among IL-8, TNF-a, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor (JAKi) in the IMbark Trial$

MPN - 298

Correlation Among IL-8, TNF-a, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor (JAKi) in the IMbark Trial

John Mascarenhas

Poster Presenter: John Mascarenhas

Thumbnail for Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

MPN - 555

Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

John Mascarenhas

Poster Presenter: John Mascarenhas

Authors

Correlation Among IL-8, TNF-a, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor (JAKi) in the IMbark Trial

Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

Mutant Calreticulin-Specific Monoclonal Antibody INCA033989 Produces Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis